FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesEMA Guidance on Trial Mgmt during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
Countdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members
2019 European Knowledge Forum: Presentation and Workshop Slides
Topics: Communication, Conference, Personal Development, Pharma Industry
Presentation
Members
